MET and thyroid cancer: The ceRNA activity of XIST versus miR-34a has an oncogenic effect in two different tumors, thyroid cancer and nasopharyngeal carcinoma, due to de-repression of different targets in different cell contexts, i.e., MET and E2F3, respectively [80,81].